News | June 05, 2023
Briefs: Ipca Laboratories, Lupin and Zydus
The company has extended its full co-operation and support to the officials of the Income Tax Department
The company has extended its full co-operation and support to the officials of the Income Tax Department
The company reported lifetime high EBIDTA of Rs. 250 crores
The company has reported total income of Rs. 2971.27 crores during the period ended March 31, 2023
Dr. Reddy's Laboratories has been issued a Form 483 with four observations
The company will submit its comprehensive response on these observations to the US FDA within the stipulated time
The company is addressing these observations
The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products, including a number of generic products focused on women’s health.
Cipla has received 8 inspectional observations in Form 483
The Durezol brand and generic had US sales of approximately US $40 million MAT for the most recent twelve months ending in Nov 2022 according to IQVIA
Subscribe To Our Newsletter & Stay Updated
